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ABSTRACT 
Mantle cell lymphoma (MCL) is a malignant B-cell lymphoma that accounts for 5-
10% of all lymphomas and tends to occur in older adults with a higher incidence in 
males. The genetic hallmark of this neoplasm is the t(11;14) translocation which 
results in overexpression of nuclear cyclin D1. The t(11;14) translocation is not 
sufficient for the development of MCL. Additional oncogenic events are required. 
 
By global gene expression analysis of MCL, the cannabinoid receptor type 1 and 2 
(CB1 and CB2), the key enzyme in leukotriene synthesis 5-lipoxygenase (5-LO) 
and transcription factor SOX11 were found to be highly express in MCL compared 
to reactive lymph nodes. In this thesis, the possible roles of these genes in MCL 
were investigated. 
In paper I, the expression of CB receptors in the B-cell lymphomas was analyzed 
by quantitative real time PCR, Western Blot and immunohistochemistry. We 
found that the majority of B-cell lymphomas expressed CB1 and/or CB2 and that 
cannabinoids induced cell death in CB1 and CB2 expressing MCL and B-CLL cell 
lines. Moreover, a metabolically stable synthetic cannabinoid reduced tumor 
burden in mice xenografted with human MCL. From this study, we can conclude 
that CB receptors are broadly expressed in B-cell lymphomas and can be a 
potential target for therapy. 
In paper II, the expression of 5-LO in the different subsets of normal B cells and 
corresponding B-cell lymphomas was investigated. Using reverse transcriptase 
PCR, Western Blot, and immunohistochemistry, we found that mantle zone, but 
not germinal centre B cells expressed high amounts of 5-LO. Similarly, primary 
MCL expressed high levels of 5-LO, while most of follicular lymphomas lacked 5-
LO expression. Furthermore, MCL cell lines were capable of producing 
leukotrienes under certain conditions. Thus, our results strongly indicate that the 
expression of 5-LO in lymphomas can mimic the expression in the developmental 
stage of the B cells from which lymphomas arise. 
In paper III, immunohistochemical analysis was used to assess a series of B-cell 
lymphomas. We found that nuclear SOX11 expression appears to detect most 
MCL, but not B-CLL or follicular lymphomas. SOX11 can therefore be considered 
as a new diagnostic marker. Importantly, a few MCL lacked nuclear SOX11 
expression. Patients with SOX11 negative MCL had worse overall survival 
compared to those with nuclear expression. 
In paper IV, the role of SOX11 in the pathogenesis of MCL was further analyzed. 
A siRNA knock down system in MCL cell line Granta 519 was used. After the 
reduction of more than 80% SOX11 mRNA and protein expression, we performed 
Affymetrix array to analyze the effect of SOX11 on global gene expression. A 
total of 26 genes were significantly downregulated in SOX11 siRNA treated cells 
compared to control cells. These genes were validated in gene expression data 
from two series of primary MCL. In these cohorts there was a strong correlation 
between SOX11 expression and the expression of DBN1, SETMAR and HIG2. 
Moreover, using ChIP, we found that SOX11 can directly target DBN1, SETMAR 
and HIG2 in MCL. 
 
The conclusions from our SOX11 studies are that SOX11 is a new diagnostic 
marker for MCL and that SOX11 may be of prognostic importance in MCL. DBN1, 
SETMAR and HIG2 are directly targeted by SOX11 in MCL.
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1 INTRODUCTION 
 
By global gene expression analysis of mantle cell lymphoma (MCL), many genes 
were found overexpressed in MCL compared to reactive lymphoid tissues. This 
thesis will focus on some of them, the cannabinoid receptor type 1 and 2, the key 
enzyme in leukotriene synthesis 5-lipoxygenase and the transcription factor 
SOX11. The aim of this thesis is to investigate the role of these genes in MCL: 
their possible function, usefulness as diagnostic markers and as potential new 
targets for therapy. 
 
1.1 B-CELL LYMPHOMA 
  
1.1.1 B cell development and function 
 
The lymphoid system acts as part of the defense mechanisms of the organism 
against pathogens. It consists of two parts: lymphoid tissue and recirculating 
lymphocytes. Two forms of lymphoid tissues have been distinguished: Primary 
(central) and secondary (peripheral) lymphoid tissue. The bone marrow and 
thymus constitute the primary lymphoid tissues involved in production and early 
selection of lymphocytes. B cells arise and differentiate to mature naïve B cells in 
the bone marrow.  Mature B cells migrate to secondary lymphoid tissues, which 
include blood, spleen, lymph node and mucosa associated lymphoid tissue 
(MALT). 
 
B cells were firstly discovered and characterized in the mid-1960s and early 1970s 
[1].  B-cell development in mice and human [2, 3] has since then been extensively 
studied. B-cells develop from hematopoietic stem cells (HSCs) located in the bone 
marrow. They first differentiate to hematopoietic multipotential progenitors (MPPs) 
and further to common lymphoid progenitors (CLPs). The CLP has the capacity to 
develop into T, B or natural killer (NK) cells, but not myeloid-lineage cells [4, 5]. 
The CLP can differentiate into the first precursor B-cell identified as the so called 
progenitor B cell or pro-B cell. 
 
 Normal B-cell differentiation begins with the first precursor B cell: pro-B cell 
which can initiate rearrangement of the immunoglobulin (Ig) heavy gene locus, 
which is the recombination of VDJ (variable, diversity and joining) genes in the 
heavy chain gene locus occurs. The next precursor stage is the pre-B cells express 
either the u heavy chain in the cytoplasm or later on express cell-surface ȝ heavy 
chain associated with surrogate light chain [6]. There are two specific markers 
expressed in the precursor B cell stages: CD34 and terminal deoxyribonucleotidyl 
transferase (TdT). The important function of TdT is that it inserts N-segments 
 2 
between the V, D and J regions during the recombination of these genes. TdT 
switches off at the end of the recombination process [7]. 
 
The rearrangement of the two Ig light chain genes also takes place in this stage 
resulting in an immature B cells with expression of a complete IgM on the cell 
surface. Even though the third B cell stage expresses IgM – the B-cell antigen 
receptor, it is unable to initiate an immune response to a foreign antigen. At this 
stage, the fate of cell is uncertain and the immature B cells may be eliminated or 
become anergic. A small part of the immature B cells (IgM+) are positively 
selected to leave the bone marrow to the spleen where they change to IgM+,IgD+  
mature B cells. Those naïve mature B cells join the circulating pool of B cells [8]. 
In the peripheral lymphoid organs, they are ready to recognize and bind antigens.  
 
Mature naïve B cells expressing CD5 circulate in the peripheral blood (PB) and the 
peripheral lymphoid organs where they occupy the primary B-cell follicles and the 
follicle mantle zone [9, 10].  The naïve B cells may be stimulated by two types of 
antigens, T-cell independent and T-cell dependent, leading to two types of B cell 
differentiation. In response to a T-cell independent antigen, mature naïve B cells 
undergo proliferation and become short-lived plasma cells that produce low 
affinity IgM. In response to a T-cell dependent antigen, naïve B cells are co-
stimulated by T-cells. They move into the centre of a primary B-cell follicle, 
where they associated with follicular dendritic cell (FDC) proliferate and 
differentiate into centroblasts and centrocytes to form a germinal centre [11, 12]. 
In the germinal centre there is a “dark zone” consisting of centroblasts and a “light 
zone” composed mainly of centrocytes.  
 
The germinal centre B cells express low level of surface Ig receptors. They also, in 
contrast to naïve B cells, memory B cells and plasma cells, express CD10 and the 
transcription factor BCL-6 [13]. Another important character of the germinal 
centre B cells is that they switch off expression of the anti-apoptosis protein Bcl-2, 
thus they are susceptible to death through apoptosis. Apoptosis of the germinal 
centre B cells can be prevented by survival and proliferation-promoting signals 
provided by FDCs and T cells [14].  
 
In the germinal centre, B cells are involved in two different genetic processes: 
somatic mutation and isotype switching. Somatic mutation occurs mainly in the 
regions of the immunoglobulin heavy and light chain variable (IgV) genes that 
form the antigen binding site, aiming to increase the affinity of surface Ig receptors. 
Since this process is partially random, these mutations may result in decreased 
affinity of the Ig receptor. Such cells can not bind to the antigen retained on the 
FDC and therefore do not receive survival signals. Almost 90% of the germinal 
centre B cells die through apoptosis; only those B cells that have an increased 
affinity to the antigen presented by FDC will bind to the antigen and receive 
survival signals from FDC [14, 15]. The isotype switch process takes place on the 
Ig heavy chain and the switch goes from IgM to IgG, IgA or less commonly to IgE. 
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Importantly, somatic hypermutation may also occur in non-Ig genes. A fraction of 
normal GC and memory B cells carry BCL6 and CD95 (also called FAS) gene 
mutations [16, 17].   
 
The centrocytes that survive in the germinal center mature into long-lived class 
switched plasma cells or memory cells [7]. Memory B cells, also called marginal 
zone B cells, comprise some of the cells in the follicular marginal zone of lymph 
nodes and spleen and also home to the bone marrow. Memory B cells express 
CD27 and strong IgM but little IgD [18-20]. Plasma cells produced in the germinal 
centre and these long-lived plasma cells enter the blood and home to the bone 
marrow. Plasma cells lack expression of B cell markers, CD19, CD20 and sIg, but 
express the adhesion molecule CD138 and CD38 [21]. 
 
Upon antigen stimulation naïve B cells become activated and can develop in three 
directions: clonal expansion and selection in GC, clonal differentiation extra-GC, 
or anergy. Eventually, B cells either die or differentiate to memory B cells or 
antibody-producing plasma cells. 
 
 
Figure1. B-cell differentiation process. 
HSC: Hematopoietic stem cell; CLP: Common Lymphoid Progenitor; GC: 
germinal center 
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1.1.2 B-cell lymphoma 
 
The incidence of malignant lymphoma in the western countries, is approximately 
20 cases per 100,000 person [22]. According to the Swedish Cancer Registry, 
about 2000 new lymphoma cases are diagnosed annually in Sweden 
(http://www.socialstyrelsen.se). Traditionally, lymphomas are classified into 
Hodgkin and non-Hodgkin lymphomas (NHL). Most NHL are derived from B or T 
cells [23]. B-cell lymphomas comprise 95% of all lymphomas [24]. They are 
clonal tumors of immature or mature B cells at various stages of differentiation. 
More than 20 different types of mature B-cell lymphoma are identified according 
to the WHO classification [23]. The most common types of mature B-cell 
lymphomas are follicular lymphoma (FL), diffuse large B-cell lymphoma 
(DLBCL), B-cell chronic lymphocytic leukaemia/small lymphocytic lymphoma 
(B-CLL/SLL), mucosa-associated lymphoid tissue (MALT) lymphoma, mantle 
cell lymphoma (MCL), marginal zone lymphoma (MZL) and Burkitt lymphoma 
(BL).  
 
Several risk factors for B-cell lymphomas have been established. One major risk 
factor for mature B-cell lymphoma is an impaired immune function, such as 
immunodeficiency and autoimmune disease. Underlying causes of 
immunodeficiency include infection with human immunodeficiency virus (HIV), 
iatrogenic immunosuppression to prevent allograft rejection or graft versus host 
disease. Patients infected with HIV have a significantly increased incidence of BL 
and DLBCL [25-27]. Certain lymphomas are related to viral infections, such as 
Epstein-Barr virus and hepatitis C virus [28-31], as well as bacterial infections, 
such as Helicobacter pylori [32]. 
 
1.1.2.1 Cellular origin of B-cell lymphomas 
 
Assessed by a combination of microscopic appearance (morphology), gene 
expression profiling and immunophenotype, most B cell lymphomas mirror the 
characters of the different normal B-cell differentiation stages [24, 33] which thus 
is an important reference for classification of the B-cell lymphomas [34]. 
 
A common viewpoint is that the different types of mature B cell lymphomas are 
“trapped” in a specific B cell stage, with a specific gene expression profile and a 
characteristic immunoglobulin somatic hypermutation status. The mutation status 
of the immunoglobulin gene is characterized as either unmutated variable-region 
genes, ongoing somatic mutation or mutated variable-region genes [35]. When 
immunoglobulin genes are somatically mutated it indicates that the B cells are of 
GC or post-GC origin.   FLs display ongoing somatic mutation and have a clear 
GC expression profile, and the tumor cells also express certain hallmarks of human 
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GC B cells, such as CD10 and BCL-6 which identify FL as a germinal centre B 
cell tumor [36, 37]. DLBLs are divided into two major groups, which resemble GC 
B cells or non-GC B cells, the latter resemble activated B cells (ABC). GC 
DLBCL subtype expresses genes that correspond well with the normal GC B cells 
and demonstrates ongoing somatic mutation, indicating its GC origin. The ABC 
DLBCL expresses genes normally induced during in vitro activation of peripheral 
blood B cells, suggesting its pre- or post-GC origin [37-39]. Among mature B cell 
lymphomas, only part of MCL and part of B-CLL express unmutated variable-
region genes, and resemble pre-GC naïve B cells [40-42] . However, according to 
recent studies on gene expression profiling, B-CLL cells with unmutated Ig V-
region genes were very similar to memory B cells that had undergone somatic 
hypermutation [43-45]. Moreover, a subset of MCL has been shown to have 
mutated Ig V region genes, indicating that some MCLs tumor cells have reached a 
GC stage of development [46-48]. 
 
 
 
Figure2. Cellular origin of human B-cell lymphomas. (Modified from [24])
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1.1.2.2 Transforming events 
 
A hallmark of mature B-cell lymphomas is the presence of chromosomal 
translocations involving the Ig genes and a variety of partner genes. As a result of 
these translocations, oncogenes come under the control of Ig gene enhancers and 
become deregulated [33, 49]. Translocation occur at three stages in B cell 
development: during V(D)J recombination in the bone marrow, during somatic 
hypermutation and during class switch in the GC [24, 33]. Three types of 
breakpoints are distinguished in the Ig loci. Two paradigms of translocation 
involved in the V(D)J recombination stage are the t(11;14) (q13 ;q32 ) BCL1-IGH 
translocation in MCL and the (14;18) (q32 ;q21 )  BCL2-IGH translocation in FL 
[50, 51]. In MCL, the translocation results in overexpression of cyclin D1, a D-
type cyclin involved in control of the cell cycle. Cyclin D1 is used as a diagnostic 
marker for MCL [52]. In FL, the translocation causes deregulated expression of 
the anti-apoptotic protein Bcl-2. Also Bcl-2 is used as a diagnostic marker since it 
can be used in distinguishing normal B cell follicles from the neoplastic follicles 
seen in FL.  
 
In other translocations the breakpoints are found within or adjacent to rearranged 
V(D)J genes, and these V region are mostly  somatically mutated [33, 53]. The 
MYC-IG translocations in BL and some translocations of the BCL6 gene in 
DLBCL show translocation breakpoints in somatically mutated V region genes [54, 
55].  
 
The third kind of translocation was detected in the chromosome breakpoints 
located in IGH switch regions. A lot of different translocations have been detected 
involving breakpoints in the IGH switch regions such as MYC in sporadic BL [56]. 
 
Although the chromosome translocations are important in B cell lymphomagenesis, 
it is not sufficient to induce lymphoma. Other genetic events are also necessary for 
lymphoma development and progression, such as mutations in tumor suppressor 
genes or deregulation of oncogenes such as MYC [24, 57, 58]. 
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1.2 MCL 
 
1.2.1 Epidemiology 
 
Mantle cell lymphoma (MCL) is a mature B-cell neoplasm thought to be derived 
from the mantle zone B cells. This lymphoma was first described around 30 years 
ago, and then defined as “centrocytic lymphoma” by the Kiel classification [34], 
and finally accepted as a separate entity in the early 1990s [59]. MCL comprises 
approximately 4-10% of all cases of non-Hodgkin lymphoma (NHL) [60]. It 
occurs in the middle-aged to older individuals with a median age of approximately 
60 years (range 29-85). This tumor has a marked male predominance with the ratio 
around 2-7:1(male: female) [61]. MCL has one of the worst prognoses among 
lymphomas, with a median survival of approximately 3 years. MCL patients 
respond well to initial therapy but the remission time is short and there is no 
therapy that can be considered as standard [62, 63]. Recently, new treatment 
protocols have markedly improved the response duration and for patients less than 
65 years of age, high dose chemotherapy and autologous stem cells transplantation 
may lead to cure [63]. However, there is still a need for new therapeutic strategies. 
Importantly, a subpopulation of MCL has a very indolent clinical course and these 
have to be identified in order to avoid overtreatment. 
 
1.2.2 Tumor pathology 
 
1.2.2.1 Morphology and site involvement of MCL 
 
Most MCL are wide-spread at the time of diagnosis with involvement of lymph 
nodes, spleen and bone marrow.  Leukemic form of MCL can occur early in the 
disease or at late stages. Involvement of extranodal sites, such as gastrointestinal 
tract and Waldeyer’s tonsillar ring [64, 65] is common. 
 
The growth pattern in lymph nodes may be diffuse, nodular or involve the mantle 
zone, sparing the germinal centers. Most likely this represents different stages of 
tumor infiltration [61]. 
 
In the early stage growth pattern (mantle zone pattern) neoplastic cells surround 
residual reactive germinal centers and replace the normal follicle mantle [66]. In 
advanced stages MCL cells grow in nodules, replacing the germinal centers, or 
diffusely infiltrate the lymph node with effacement of the normal architecture [67]. 
Four cytologic variants of MCL can be recognized; a small cell variant, a marginal 
zone-like variant, a pleomorphic variant and a blastoid variant [67, 68]. The 
blastoid variant and pleomorphic variant are considered as aggressive variants and 
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are associated to a worse prognosis [68]. Recent findings suggest that the blastoid 
MCL may arise in patients with previously diagnosed classical MCL and therefore 
represents histological transformation of the original neoplastic clone rather than a 
de novo tumor [69]. 
 
1.2.2.2 Phenotype 
 
The phenotype of MCL cells is similar to mature, naïve B cells expressing B-cell 
antigens (for example CD19+, CD20+, CD22+), and IgM and/or IgD surface 
immunoglobulins often associated with  the lambda light chain [67]. MCL cells are 
usually CD5+ and CD43+, FMC-7+, but CD23- , BCL6 as well as CD10-. Some 
MCL tumors may be CD5- or weakly positive CD23 [70]. The phenotypic variants 
make the diagnosis difficult and some MCL may erroneously be diagnosed as CLL. 
The clinical and biological significance of these phenotypic variants is unclear. 
 
1.2.3 Genetics 
1.2.3.1 Antigen receptor genes 
 
The immunoglobulin genes in MCL are rearranged. According to its origin from 
pre-germinal centre cells, the majority of MCL cases have no or very few somatic 
mutations in V-gene sequence of Ig (VH) genes. However, 15-40% of the MCL 
cases show somatic hypermutations in immunolobulin genes, suggesting that those 
tumors may originate from a subset of B cells that was experienced in GC 
environment [47, 71, 72]. In contrast to CLL, the VH gene mutational status in 
MCL is not associated with patient outcome [47, 73, 74]. 
 
1.2.3.2 Cyclin D1 overexpression 
 
The genetic hallmark of MCL is the t(11;14)(q13;q32) translocation. This 
translocation results in the positioning of the CCND1 gene under control of the 
immunoglobulin heavy-chain gene enhancer and leads to the overexpression of 
cyclin D1 mRNA and protein [75, 76]. The deregulated expression of cyclin D1 is 
present in almost all MCL and is considered the primary molecular event in the 
pathogensis of MCL. Cyclin D1 is not detectable in normal B cells which instead 
may express cyclinD2 and/or D3 [61, 77]. 
 
Cyclin D1 cloning identified two major mRNA transcripts of approximately 4.5kb 
and 1.5kb that differ in the length of the 3’ untranslated region (UTR) but contain 
the whole coding region that generate a 36kDa polypeptide. Around 4-10% of 
MCLs lacks the long transcript but overexpress the shorter transcript. The short 
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transcript lacks the destabilizing AUUUA sequence in the 3’ UTR. The loss of this 
regulatory sequence is caused by the secondary rearrangement in the 3’ region of 
CCND1 gene [52, 78], or by genomic deletions and point mutations [79]. The 
short transcript has an increased half-life and is related to high level of cyclin D1 
protein expression, increased proliferation and poor survival of the patients [76, 
79-81]. 
 
Cyclin D1 binds to cyclin-dependent kinase 4 (CDK4) and CDK6 to form a cyclin 
D1-CDK4/CDK6 complex. These complexes promote phosphorylation of the 
tumor suppressor gene retinoblastoma protein (pRB). In normal cells, RB binds to 
E2F and then blocks its ability to activate the essential genes required for S phase 
entry and DNA replication. In MCL hyperphosphorylation of RB1 will lead to 
release of the E2F transcription factor which then leads to progression of the cell 
cycle into the S phase [82, 83].  
 
There are two families of CDK inhibitors that can regulate the activity of 
CDK/cyclin complex. The INK4 family is specific to CDK4/CDK6 whereas the 
Cip /Kip family, including p27, whose action is broad and targets all the different 
CDK activities [84]. p27 together with the cyclinE-CDK2 complex may regulate 
the late G1 phase and the G1-S phase transition. Several ways of deregulating p27 
function in MCL have been described. MCLs have normal p27 mRNA expression 
levels but increased p27 protein degradation activity by the proteasome pathway 
[85]. Furthermore, p27 is recruited by CDK4-cyclin D1 complexes which then 
prevent the p27-dependent inactivation of CDK2-cyclin E and G1 cell cycle arrest 
[86].  
 
1.2.3.3 Cyclin D1 negative MCL 
 
Some cases of MCL are negative for cyclin D1 and the t(11;14), but this particular 
subset of tumors share the same morphology, phenotype, global expression profile 
and clinical presentation as conventional MCL [81, 87, 88]. These cases have a 
high expression of cyclin D2 and cyclin D3. Deregulation of cyclin D2 is in some 
cases a result of t(2;12)(p12;p13) translocation fusing cyclin D2 to the kappa light 
chain locus [89]. It is difficult to recognize the cyclin D1 negative MCL since 
there are no specific diagnostic markers for this entity. 
 
1.2.3.4 Secondary genetic events 
 
The t (11; 14) translocation is the important event for MCL initiation, but not 
sufficient for the development of MCL. Instead additional oncogenic events in the 
progression of MCL are needed [57, 58].  
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Such events could be deregulation of key genes involved in cell cycle control. 20-
30% of blastoid variants have deletions of the CDKN2A locus on 9p21 [90] which 
encodes two key regulatory elements, the CDK4 inhibitor INK4a and the p53 
regulator ARF.  INK4a deletion together with cyclin D1 dysregulation increases 
the amount of active cyclin D1-CDK4 complexes, and then promotes G1/S phase 
transition in MCL. ARF stabilize p53 protein by negatively regulating MDM2-
mediated degradation. Mutations in the TP53 gene itself is associated with a poor 
prognosis in MCL [91].  
 
Another important oncogenic alteration in the pathogenesis of MCL is in genes 
targeting the DNA damage response pathway. The most common secondary 
cytogenetic alterations in MCL are the deletions of the region on 11q22-23 
including the ataxia-telangiectasia mutated (ATM) genes [92]. ATM plays an 
important role in the activation of p53 in response to DNA damage, such as double 
strand break lesions (DSBs) [93]. ATM deletion has been reported in 40-75% of 
MCL [94]. 
 
Deregulation of survival and apoptosis pathways may also contribute to the MCL 
oncogenesis. The most relevant apoptotic pathway is the BCL2 system. The 
overexpression of BCL2 protein in MCL can inhibit the cytochrome C1 system 
and thus prevent caspase 9-mediated cell death [95]. 
  
1.2.4 Prognosis and predictive factors 
 
The most important prognostic marker in MCL patients is a high mitotic index or 
high frequency of cells expressing the proliferation-associated antigen ki67 [96, 
97].  Gene expression analysis identified a series of genes which predict the 
survival in MCL patients [81]. This set of genes is called the proliferation 
signature and consists of 20 genes. Recent studies reported that a five-gene model 
that can predict survival in MCL using quantitative RT-PCR. The five-gene 
signature consists of RNA, MYC, TNFRSF10B, POLE2, and SLC29A2 [98]. 
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Figure3. Molecular pathways involved in the pathogenesis of MCL. Proteins 
overexpressed are shown in red. (Modified from [99]) 

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1.3 THE ENDOCANNABINOID SYSTEM 
 
The endocannabinoid system consists of the endocannabinoids, the cannabinoid 
receptors, CB1 and CB2 and the enzymes involved in the endocannabinoid 
synthesis (N-acyl phosphatidylethanolamine phospholipase D, NAPE-PLD) and 
degradation (fatty acid amid hydrolase, FAAH) [100-102].   
 
1.3.1 Cannabinoids 
 
There are three types of cannabinoids, including the natural plant derived 
cannabinoid, such as cannabidiol (CBD) and ¨9-tetrahydrocannabinol (THC), 
endogenous cannabinoids, endocannabinoids which are endogenous agonists 
to CB1 and CB2and synthetic cannabinoids which are developed in the 
laboratory. The endocannabinoids N-arachidonoylethanolamine (anandamide, 
AEA) [103] and 2-arachidonoyl glycerol (2-AG) are best studied [104]. 
Commonly used synthetic cannabinoids are WIN 55,212-2, (R)-
methanandamide [105, 106]. 
 
The first selective antagonist to the CB1 receptor, SR141716A (Rimonabant 
or Acomplia) [107] was introduced in the mid-1990, SR141716A showed 
high binding affinity to CB1, but low to CB2 [108]. Rimonabant can 
significantly reduce the food intake and body weight gain in obese animals 
[109, 110].SR144528 is the first selective and active antagonist to CB2 
receptor [111]. 
 
1.3.2 Cannabinoid receptors and their functions 
 
1.3.2.1 Cannabinoid receptors 
 
In the early 1990s, the two seven-transmembrane G-proteins coupled (GPCR) 
receptors, CB1 and CB2, were discovered [100, 101, 112]. CB1 was denoted 
the central cannabinoid receptor based on its predominant expression in the 
CNS, while CB2 was denoted the peripheral cannabinoid receptor based on its 
expression in the peripheral immune system. Recent evidence show that CB1 
can also be expressed in non-neuronal tissues, such as immune cells and 
reproductive tissues [113, 114], and CB2 is expressed also in CNS [115]. The 
CB1 receptor is highly conserved across species, while the CB2 receptor is 
less conserved. The two human receptors have only 44% identity in the total 
protein sequences [101], but they have a conserved ligand binding region 
[116].  Two splice variants of CB1 have been described, CB1a and CB1b. 
They are expressed at low levels in a variety of tissues and display increased 
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binding affinity for WIN 55,212-2 compared to the full length CB1 receptor 
[117].  
 
In addition to these two receptors, other receptors such as transient receptor 
potential vanilloid type-1 (TRPV1) receptor can also bind cannabinoids 
including AEA [118]. The G protein coupled receptor GPR55 expressed in the 
brain and some peripheral organs and sharing little identity with CB1 and 
CB2, was recently discovered to bind several cannabinoids [119]. 
 
1.3.2.2 The functions of CB receptors 
 
The major function of CB1 is inhibition of neurotransmitters release, while 
CB2 regulates cell migration and cytokine release in the immune system [120]. 
In addition to their roles in neuromodualtion and immune function, the 
cannabinoid signaling pathway is also involved in the regulation of cell fate, 
including activation of mitogen-activated protein (MAP) kinase cascades: 
extracellular-signal-regulated kinases (ERK), c-Jun-N-terminal kinase (JNK) 
and p38, and ceramide generation [120, 121]. 
 
1.3.3 Cannabinoids and cannabinoid receptors in cancer 
 
The natural cannabinoid, THC, was firstly used as an anti-cancer agent for 
treatment of Lewis lung carcinoma in 1975 [122].  However, there were no 
further studies in this field carried out until in the 1990s. Since then, great 
effort has been put into the investigation of the anti-cancer effect of 
cannabinoids in different types of cancer [121].  
 
Increased expression of the CB1 and CB2 receptors has been shown in several 
cancers, such as lymphoma, acute myeloid leukemia (AML), breast cancer, 
hepatocellular carcinoma, skin cancer and prostate cancer cells in comparison 
to their normal counterparts [123-127]. Interestingly, high expression of CB1 
receptor in the prostate, pancreatic cancers patients is associated with worse 
outcome compared to those with less expression [128, 129]. However, in 
hepatocellular carcinoma, overexpression of CB1 and CB2 receptors 
correlates with improved prognosis of patients [130]. 
 
Cannabinoids have been found to induce tumor cell apoptosis, cell cycle arrest, 
anti-angiogenic activity and reduce migration of tumor cells [120, 121]. The 
effects of cannabinoids on several cancers have been reported. In colon cancer, 
glioma and leukemia, THC binding to CB1 receptor can induce apoptosis 
through dephosphorylation of ERK and AKT and activation of BAD [131-
133]. In prostate cancer, AEA induced a decreased EFGR expression by 
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acting on CB1 receptor, which in turn inhibits the EGF-stimulated growth of 
tumor cells [134].  
 
In vivo, anti-tumor effects of cannabinoids have mainly been studied in 
xenograft models. If tumors express CB receptors, the tumor cells are targeted 
by cannabinoids with in turn inhibiting tumor growth [122, 135, 136].  
However, tumor cells lacking expression of CB receptors may not been 
affected by cannabinoids [137]. In human study, Salazar et al. showed that 
targeting CB1 receptor with THC in human glioma cells caused cell death via 
ceramide accumulation, ER stress, autophagy and ultimately apoptosis [138]. 
 
Thus, cannabinoids in combination with other conventional therapy could be 
used in the treatment of cancers.  
 
1.4 5-LIPOXYGENASE 
 
1.4.1 Regulation of 5-LO expression and activity 
 
The human 5-LO is a 674 aa, 78 kDa enzymatic protein. The enzyme contains 
a non-heme iron involved in catalysis which is active in its ferric (Fe3+) form 
[139]. 5-LO is expressed mainly in leukocytes, in line with the function of 
LTs as mediators of immune reactions. Granulocytes, mast cells, dentritic 
cells, monocytes/macrophages and B lymphocytes express 5-LO [140]. 
 
A few factors can regulate the 5-LO expression and activity. The regulation of 
5-LO expression at transcriptional level is complex and is related to the 
methylation of 5-LO promoter [141]. Also the localization of the enzyme 
affects its function. Phosphorylation of 5-LO can modulate its subcellular 
localization as well as its activation [142].  
 
In resting cells, 5-LO is localized in either the cytosol or inside the nucleus. 
Upon activation, 5-LO moves to the nuclear membrane, where interacts with 
cytosolic phospholipase of class A2 (cPLA2) and 5-LO activating protein 
(FLAP) for LT biosynthesis. The regulation of 5-LO activity is influenced by 
many factors. Calcium ions in combination with phosphatidylcholine (PC) or 
coactosin-like protein (CLP) can stimulate 5-LO translocation to the nuclear 
membrane and induce 5-LO activity [140]. 
 
1.4.2 Biosynthesis of leukotrienes  
 
5-LO has a central role of biosynthesis of leukotrienes (LTs). LTs are lipid 
messengers involved in autocrine and paracrine cellular signaling. They are 
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synthesized from arachidonic acid (AA). In the first step 5-LO in concert with 
FLAP converts AA to 5-HPETE and 5-HPETE can be further converted to an 
intermediate leukotriene A4 (LTA4). LTA4 can be hydrolyzed by the enzyme 
LTA4 hydrolase to leukotriene B4 (LTB4) or conjugated with glutathione by 
LTC4 synthase to produce leukotriene C4 (LTC4) [143, 144]. LTC4 can be 
future converted to leukotriene D4 (LTD4) and leukotriene E4 (LTE4).  LTC4, 
LTD4 and LTE4 are also called cysteinyl leukotrienes (cys-LTs). 
 
 
 
 
 
Figure4. 5-lipoxygenase (LO) activation in the cell.  
AA: Arachidonic acid. CLP: Coactosin-like protein.  
cPLA2: cytosolic phospholipase A2.  
FLAP: 5-LO activating protein. LTs: leukotrienes (modified from[140]) 
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1.4.3 The role of 5-LO and LTB4 on B cells 
 
 
Biosynthesis of LTs from AA has for a long time been thought to be restricted 
to myeloid cells. Not until in the 1990s, the expression of 5-LO and the ability 
of human B lymphocytes to convert AA to LTB4 was reported [145, 146].  
The activation of LT synthesis in B cells is quite different from myeloid cells. 
Myeloid cells produce LTs upon stimulation with calcium. However, the 
intact B cell can synthesize LTB4 after stimulated by glutathione depleting 
agents (Diamide) plus AA and calcium. It seems that the cellular oxidative 
status is important for inducing biosynthesis of LT in intact B cells, although 
the mechanism of activation of leukotriene biosynthesis is unclear [147, 148]. 
 
 
The major activities of LTB4 include inflammatory cell recruitment, 
activation of inflammatory cell effector functions, and prolongation of 
inflammatory cell survival [149]. LTB4 can activate and stimulate effector 
functions of lymphocytes by affecting the proliferation and differentiation of 
B cells and the expression of CD23 [150]. 
 
Meanwhile, some studies focused on the biological effects of LTB4 on B cells. 
LTB4 in synergy with interleukin-2 (IL-2) and interleukin-4 (IL-4) played a 
role in B cell differentiation, which was measured by the increased CD23 
expression, DNA synthesis, cell numbers and the increased secretion of IgG 
and IgM [150, 151]. 
 
1.4.4 The role of 5-LO and leukotrienes in cancer 
 
1.4.4.1 The role of 5-LO in cancer 
 
Over expression of 5-LO has been found in several cancers, such as prostate, 
lung, pancreas, bladder, breast, colon, testicle, esophagus and B-CLL [152-
159]. The high expression of 5-LO in tumor tissues make it possible to target 
the cancer cells by inhibiting 5-LO activity. 
 
Imbalance between cellular proliferation and cell death is the hallmark of 
cancer. In colon cancer, inhibition of 5-LO significantly inhibited the 
activation of NFțB and subsequent cell proliferation [160]. In prostate cancer 
cells, EGF and neurotensin-induced cell growth via the MAPK pathway is 
highly dependent on the 5-LO activity [161] 
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In vivo study, it was found that 5-LO inhibition by zileuton significantly 
inhibited esophageal carcinogenesis in rats [162]. 
 
The expression and activity of 5-LO in malignant B cells was first 
investigated in B-CLL in 1995 [147]. Subsequent studies showed that B-CLL 
cells produced LTs, and specific LT biosynthesis inhibitors counteracted 
CD40-dependent activation of B-CLLs. The effects were measured by the 
inhibition of CD40-induced DNA synthesis and CD40-induced expression of 
CD23, CD54 and CD150 [159]. 
 
1.4.4.2 The role of leukotrienes in cancer 
 
LTB4 can prevent apoptosis of pancreatic carcinoma both in vitro and in vivo. 
Treatment with LY293111, a LTB4 receptor antagonist in pancreatic 
carcinoma xenografted mice induced tumor cell apoptosis and resulted in the 
inhibition of tumor growth [153, 163]. Similar result was found in another 
study with anaplastic large-cell lymphoma (ALCL). LY293111 treatment has 
been shown to inhibit the proliferation of an ALCL cell line and induce G1-S 
cell cycle arrest [164].  
 
Cys-LTs are produced by mast cells, macrophages, basophils and 
eosinophils[165]. These substances are potent constrictors of human bronchial 
smooth muscle cells both in vitro and in vivo [166]. Cys-LTs also increase 
vascular permability in postcapillary venules and recruit inflammatory cells 
[167]. It is well known that chronic inflammation can increase the risk of 
cancer. It was reported that in inflammatory bowel disease, LTD4 can activate 
ȕ-catenin signaling, resulting in up-regulation of Bcl-2 which could increase 
tumor cell survival [168]. 
 
It seems that the 5-LO may be involved in cancer biology, and treatments 
aimed at inhibiting its activity should improve the efficacy of conventional 
treatments. However, before my study started, the expression, the activity and 
the function of 5-LO in MCL was still unknown. It is challenging to 
investigate the possible role of 5-LO in MCL. 
 
1.5 THE SOX TRANSCRIPTION FACTORS  
 
SOX (SRY-related HMG-box) proteins are a family of transcription factors 
(TFs) which comprises 20 members in most vertebrates [169]. SOX proteins 
were named due to their high similarity to the sex-determining region on the 
chromosome Y (Sry)–related high-mobility (HMG) group box proteins. Thus, 
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members of SOX gene family were first identified by their homology to the 
HMG domain of the testis-determining factor in the 1990s [170].  
 
1.5.1 The molecular features of SOX proteins 
 
1.5.1.1 HMG domain 
 
SOX proteins bind to DNA sequence-specifically via a HMG domain with a 
consensus motif: 5’-(A/T) (A/T) CAA (A/T) G-3’, which allow them to function 
as TFs. This HMG domain is highly conserved in the SOX family [171, 172] . 
Unlike most other DNA binding TFs which mainly target the major groove, SOX 
proteins contacts the minor groove of DNA [173], thus leaving space for other TFs 
to bind the major groove. SOX proteins may therefore bring together several 
regulatory elements and promote the formation of protein complexes [174].  
  
The SOX proteins have been subdivided into eight groups (A, B1, B2, and C-H) 
based on the degree of homology within and outside the HMG domain. SOX 
proteins belonging to the same group usually have more than 80% sequence 
identity in their DNA binding HMG-domain and share other well conserved 
regions [175-177]. 
 
1.5.1.2 DNA interaction 
 
The HMG box domain performs the functions of DNA binding, DNA bending, 
protein interactions, and nuclear import and export.  SOX proteins have their own 
unique preference for the DNA binding hexametric core sequence, 5’-(A/T) (A/T) 
CAA (A/T) G-3’. For instance, SOX9 and SOX17 prefer 5’AG, but SOX9 prefers 
3’GG, and SOX17 prefers 3’G nucleotide [176, 178]. After binding to DNA, SOX 
proteins also have the ability to bend DNA which may be an essential SOX 
function. SRY and SOX2 mutations which directly interfere with DNA bending 
lead to a disease phenotype [179, 180].  
 
SOX proteins are capable to bind DNA, but the binding affinity is lower than other 
TFs.  How to improve the binding efficiency?  Several mechanisms that could 
improve the binding have been identified which will be discussed below. Also, 
each SOX protein may be expressed in more than one cell type. Furthermore 
several SOX proteins may use similar DNA binding motifs. How, then, can SOX 
proteins recognize their appropriate target genes? To answer these questions, 
another important property of SOX proteins, protein interactions, must be 
mentioned. 
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1.5.1.3 Protein partner and co-factors of SOX proteins 
 
SOX protein can interact with three classes of proteins to activate or repress the 
transcription of the targeted genes. These proteins include (1) other TFs; (2) 
importins, required for the nuclear import of SOX proteins; and (3) adaptor 
proteins, which link SOX factors to other proteins. 
 
SOX interactions with other TFs 
 
 Several TF proteins from different families have been reported to partner with 
SOX proteins, with the function either to activate or repress transcription from 
target promoters. The first described example is SOX2 interacting with Oct3 to 
regulate the expression of fibroblast growth factor 4 gene (Fgf4) in embryonic 
stem cells [181]. SOX2 can also pair off with other partners in other cell lineages. 
Kamachi et al reported that Sox2 and TF Pax6 act cooperatively to activate 
transcription from the enhancer of the lens-specific gene DC5 both in vivo and in 
vitro [182]. 
 
SOX proteins can also recruit transcriptional repressors binding to promoter 
sequences. SOX6 and CtBP2 interact to repress Fgf3 transcription through the 
PS4A promoter [183] . SOX proteins may be expressed in multiple cell types and 
their target genes in a particular tissue are determined by the presence of specific 
protein partners. 
In all these cases, the SOX proteins and their partners interact through their DNA 
binding domain.   
 
Nuclear import proteins 
 
In addition to binding to DNA and mediating interactions with TFs, the HMG 
domain also contains signals for nuclear import. This process is mediated by a 
group of transporter proteins called importins, which recognize a nuclear 
localization signal (NLS) in the protein. Two NLS sequences localized at N and C 
termini of the HMG domain have been identified in some SOX proteins (SRY and 
SOX9) [184]. Nuclear import of SRY is mediated by importin ȕ, which requires 
the HMG domain C-terminal NLS of SRY. Mutation in this NLS results in 
cytoplasmic accumulation of SRY and sex reversal [185, 186]. 
 
Adaptor proteins 
 
Apart from HMG domain, other parts of the SOX proteins also play a role in the 
regulation of gene transcription. The protein PSD-95, Discs large, zO-1 (PDZ) 
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class can interact with SOX proteins on other domain. PDZ proteins are a group of 
adaptor proteins which can assemble multi-protein complexes in appropriate 
regions of the cells. They usually bind to C-terminal residues of other proteins 
[187]. During B cell development, both SOX4 and IL-5 have important functions. 
By using yeast two-hybrid system, interleukin 5 (IL-5) mediated transcriptional 
regulations via an interleukin 5 receptor Į subunit (IL-5RĮ) interacting protein, 
syntenin, was identified [188]. When IL-5 regulate SOX4 activation through its 
receptor IL-5RĮ, syntenin acts as an adaptor to connect SOX4 with IL-5RĮ [188]. 
 
 
 
 
 
 
 
Figure5. Three different types of SOX protein-protein interaction. Modified 
from [189].
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1.5.1.4 Transactivation and transrepression 
 
Transactivation domain (TAD) has been identified in many SOX proteins 
including SOXB1, SOXC, SOXE, and SOXF groups. TADs are well conserved 
between the different members of the same SOX group, but show only little 
similarity among different groups [176]. In the SOXC group, the TAD is localized 
in the C-terminal of the protein and corresponds to the last 33 amino acids [190]. 
In contrast, the SOXE and SOXF proteins have two separate TADs [191]. 
 
Most SOX proteins predominantly function as transcriptional activators. The 
SOXB group is of particular interest in that. It includes a B1 subgroup of three 
transcriptional activators: SOX1, SOX2, and SOX3, and a B2 subgroup of two 
transcriptional repressors (SOX14 and SOX21). Since these five genes have very 
similar HMG boxes and overlapping expression patterns, the target genes must be 
regulated by the counterbalance of activating and repressing SOX proteins [176, 
192].  SOX13, another interesting SOX protein, can directly bind T-cell factor 
(TCF1) and modify its activity, and thereby regulate the developmental fate of two 
lineages of T lymphocytes [193]. From the evidences described above, it seems 
that the transcriptional actions of the SOX proteins are not only related to the 
cellular context, but also dependent on the context of the target gene. 
 
1.5.1.5 Post-translational modifications of SOX proteins  
 
Post-translational modification (PTM) regulates the activity, stability and partner 
protein interactions of TFs [194]. The most common PTMs include modification 
of SOX protein by phosphorylation, acetylation, and sumoylation  [195]. 
 
Phosphorylation of SOX proteins has been best studied in SOX9. SOX9 is 
phosphorylated by the cyclic AMP-dependent protein kinase (PKA) at two 
residues resulting in increased DNA binding efficacy and transcriptional activity 
of SOX9 [196].Furthermore, phosphorylation of SOX9 can modify the nuclear 
translocation of SOX9 protein in the testis [197]. 
 
Acetylation regulates the function of SRY in sex determination by influencing its 
subcellular localization [198]. Lysine residues are important for another PTM, 
sumoylation. For examples, SOX2, SOX4 and SOXE proteins can be sumoylated 
or ubiquitinated in vitro, with the variable consequences for DNA binding 
efficiency and transcriptional activity [199-201].  
 
These findings will be of critical importance for our understanding the precise 
mechanisms of SOX function. 
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1.5.2 The roles of SOX proteins in vivo  
 
The SOX proteins have broad functions, and many members contain the ability to 
regulate several different aspects of development. Furthermore several SOX 
protein may be involved in one developmental process. The following table shows 
the most common roles of SOX proteins in vivo. 
 
 
Table1. Roles of SOX proteins in vivo 
 
Group Sox members Majors roles 
A SRY Sex determination [202] 
B1 SOX1,SOX2,SOX3 Neurogenesis and eye development  
[203, 204] 
B2 SOX14, SOX21 Neurogenesis: counteraction of SOX1-3 to 
promote neuronal differentiation [205] 
C SOX4,  
SOX11,  
SOX12 
Lymphopoiesis [206]  
Neurogenesis [207] Organ development 
[208] 
unknown 
D SOX5,  
SOX6, 
 SOX13 
Gliogenesis  [209] 
 Erythropoiesis [210] 
Lymphopoiesis [193] 
E SOX8, SOX9, 
SOX10 
Sex determination [211] 
Neural crest development [176] 
F SOX7, SOX17, 
SOX18 
Cardiogenesis [212] 
Hair follicle development [213] 
G SOX15 Skeletal muscle regeneration [214] 
H SOX30 Unknown 
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1.5.3 SOX11  
 
SOX11 together with SOX4 and SOX12 constitute the SOXC group. These one-
exon genes are highly conserved among vertebrates [175]. All SOXC members 
contain two functional domains, the HMG box domain, located in the N-terminus, 
and the TAD, located at the C-terminus [190]. They share 84% identity in the 
HMG box and 67% identity in TAD. They are co-expressed in many tissues and 
might functionally interact in many processes. This thesis will focus on the role of 
SOX11 in MCL. 
 
1.5.3.1 The human SOX11 molecular features 
 
The human SOX11 gene was first cloned and mapped in 1995 [215]. It was 
mapped to chromosome 2p25.  The full length cDNA is 8743bp possessing a long 
3’ UTR. The human SOX11 protein has 441 amino acids (aa) with molecular 
weight of 46.7 kDa [216, 217]. In SOX11, the HMG box is in the N-terminal third 
(47-122) and the TAD domain at the C-terminal (408-441) [190, 216].  
 
 
 
Figure6. The structure of human SOXC proteins, highlighting the two 
functional domains in each protein. 
HMG: High-mobility group box DNA binding domain; 
TAD: Transactivation domain.
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1.5.3.2 The expression of SOX11 
 
SOX11 is widely expressed during organogenesis. It is also highly expressed in 
human and mouse fetal tissues, such as CNS and PNS, lung, kidneys, 
gastrointestinal tract, pancreas, spleen, gonads, bronchial arches and mesenchyme 
[208, 215, 218]. The SOX11 expression is restricted after birth, and only low 
transcript levels of SOX11 were detected in adult colon, small intestine, heart and 
brain [219]. High level of SOX11 is however present in normal human adult 
prostate tissue and mouse brain [220, 221]. SOX11 expression was not detected in 
any other adult human or mouse tissues [215].  
 
1.5.3.3 The functions of SOX11 
 
The expression pattern of SOX11 can give some insight into the biological role of 
this protein. Several pieces of evidence suggested that SOX11 may be essential for 
embryonic development in both CNS and PNS, tissue remodeling including heart 
arterial outflow tract formation, skeletal development, and the developing anterior 
eye segment [208, 218, 222]. SOX11, together with SOX4, can regulate the 
differentiation of neuronal progenitors [207]. Both SOX4 and SOX11 are required 
during development of the sympathetic nervous system, but they perform different 
functions in different stages [223]. SOX11 is involved in the transcriptional 
regulation of specific gene expression programs in adult neurogenesis, and it 
functions at the stage of the immature neuron by regulating early steps in neuronal 
differentiation, migration, and maturation [221]. SOX11 is able to control 
morphological maturation, such as neurite growth and modulate the peripheral 
nerve regeneration following the nerve injury [224, 225]. Several studies have 
shown that the SOX11 protein is able to cooperate with protein partners. SOX11 
may synergize with Brn-1/Brn-2 and exhibit cooperate effects in glial cells [226, 
227].  
 
In the mouse, two genes which are direct targets of SOX11 protein have been 
identified, Tubb3 and Tead2. Tubb3 is the class-III ȕ-tubulin gene. Tead2 is TEA 
domain family member 2, a transcription factor involved in mediating the intrinsic 
organ growth function of the Hippo signaling pathway [228].   
 
In summary, SOX11 has critical roles in embryonic neurogenesis and tissue 
remodeling. It also required for neuron survival and neurite growth. However, to 
date, little is known about the role of SOX11 in hematopoiesis. SOX4 is so far the 
only gene in SOXC group has been found to be important in lymphocytes 
development.  In SOX4-deficient mice, B cell development can be blocked at the 
pro-B stage [229, 230].  
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1.5.4 SOX11 in cancer 
 
High expression of SOX11 and SOX4 has been found in most medulloblastomas. 
The different expression profiles of the two SOX genes in medulloblastomas may 
reflect their maturation-dependent expression characteristics during normal tissue 
development, and they may supply cell specific markers for tumor classifications 
[231]. 
 
Increased SOX11 expression was also reported in gliomas [219]. However, recent 
evidence showed that human glioma-initiating cell (GIC) from malignant gliomas 
lacked SOX11 expression. Overexpression of SOX11 prevented tumorgenesis by 
inducing neuronal differentiation. Clinical studies also showed that 
downregulation of SOX11 mRNA correlated with a significant decrease in 
survival [232]. These studies suggest that lack of SOX11 expression was 
correlated to a less differentiated and more aggressive tumor subtype. Also in 
ovarian carcinoma, lack of SOX11 is associated to poor prognosis [220]. On the 
other hand, glioma-directed cytotoxic T lymphocytes (CTLs) were identified to 
target SOX11 positive gliomas [233].  
 
Thus, it is possible that SOX11 have different effects on tumor cells based on 
different primary transformation mechanisms. Our understanding of these 
functions is just at its beginning. More studies are needed to clarify the 
complicated roles of SOX11 in regulating tumor proliferation and survival in 
multiple pathological processes.  
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2 AIMS OF THE PRESENT STUDY 
 
The general aim of the study was to broaden our understanding on the 
molecular pathogenesis of MCL and to identify possible new therapeutic 
targets for this disease. 
 
 The specific aims were: 
 
1) To investigate the expression and functional roles of cannabinoid 
receptors in MCL as well as other malignant B-cell lymphomas. To study 
the possible of the anti-tumor effects of cannabinoids in an animal model 
for MCL. 
 
2) To study the expression and function of 5-lipoxygenase on different 
subsets of B cells and MCL. 
 
3) To determine if SOX11 can be used as a diagnostic and prognostic marker 
in MCL. 
 
4) To further investigate the role of SOX11 in the pathogenesis of MCL. 
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3 COMMENTS ON METHODOLOGY 
 
The methods used in this thesis are described in the individual papers. Some 
methodological considerations are discussed below. 
 
3.1 MATERIALS 
 
3.1.1 Cell lines and patient samples 
 
In this thesis, four MCL cell lines Rec-1, Granta 519, JeKo-1, and JVM2 were 
used. All these MCL cell lines carry the t (11; 14) translocation. Two B-CLL 
cell lines (MEC1 and MEC2), two BL cell lines (Raji and Namalwa), and a 
plasma cell line (SKMM-2) were also used. 
 
Different types of B-cell lymphomas diagnosed in the Department of 
Pathology at Karolinska University Hospital were used. (Paper I, II, III, IV) 
 
3.1.2 Animal model 
 
Ten week old female immunodeficient NOD/SCID mice lacking B cells and T 
cells were subcutaneously injected with the MCL cell line JeKo. Tumors were 
visible in 3 weeks. (Paper I) 
 
3.2 METHODS  
 
3.2.1 Quantitative real time PCR 
 
In molecular biology, real-time PCR is a widely used method based on the 
PCR. It is used to amplify and quantify a gene product. Two common 
methods for detection of products in real-time PCR: non-specific fluorescent 
dyes which intercalate with any double-strand DNA, and sequence-specific 
DNA probes consisting of oligonucleotides which are labeled with a 
fluorescent reporter which permits detection only after hybridization of the 
probe with its cDNA target. We used SYBR green binding to amplified cDNA 
and the ¨¨CT method to calculate real-time PCR results. Ǻ-actin was used as 
the endogenous control. (Paper I, IV) 
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3.2.2 Western Blot (WB) 
 
WB separate and identify proteins based on the molecular size. Proteins are 
separated by gel electrophoresis. The proteins are then transferred to a PVDF 
membrane where they are exposed to a primary antibody specific to the target 
protein. Thereafter a horseradish peroxidase (HRP)-linked secondary antibody 
is applied. The HPR cleave a chemiluminescent substance, and the reaction 
product produces luminescence which can be detected by photographic film 
or image instrument.  
Using WB, we detected the protein expression of CB1, 5-LO and SOX11. 
(Paper I, II, III, IV)    
 
3.2.3 Immunohistochemistry (IHC)  
 
IHC is the most commonly applied immunostaining technique. It is widely 
used in the basic research to understand the distribution and localization of 
biomarkers and differentially expressed proteins in the different tissues. 
Labeled antibodies bind proteins in tissue sections, which then are visualized 
by a marker such as enzyme. The most common enzyme is HRP which is 
reacted with 3, 3’-Diaminobenzidine (DAB) to produce a brown staining. The 
distribution of the stain can be examined by light microscopy. 
 In our studies, we used peroxidase-DAB system to detect CB1, 5-LO and 
SOX11 in lymphomas. (Paper I, II, III) 
 
3.2.4 Cell death ELISA 
 
In our paper I, we used cell death ELISA to examine R (+)-MA induced cell 
death via CB1 and CB2 receptors in lymphoma cell lines. The cell death 
ELISA is a quantitative sandwich ELISA that detects histone and 
intranucleosomal DNA fragmentation by binding two different monoclonal 
antibodies. It allows specific determination of mononucleosomes and 
oligonucleosomes from the cell lysates. (Paper I) 
 
3.2.5 RNA interference (RNAi) 
 
Small interfering RNAs (siRNA), also known as short interfering RNAs, is a 
class of 20-25 nucleotides double-strand RNA (ds RNA).  
siRNA induces effective posttranscriptional silencing of specific target genes 
in a variety of organisms. RNA interference (RNAi) is the process by which 
dsRNA induces specific inhibition of gene expression through degradation of 
complementary messenger RNA (mRNA). In vivo, long dsRNA is processed 
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by an enzyme called Dicer to form 21-25 nucleotide dsRNA-siRNA . siRNA 
is incorporated into a large protein complex named RNAi-induced silencing 
complex (RISC), then the antisense strand of the siRNA is used by RISC to 
guide mRNA cleavage, so promoting mRNA degradation. siRNA can also be 
exogenously introduced into cells by different methods to specifically 
knockdown a gene of interest. 
 
Using RNAi technology, we successfully knocked down the SOX11 gene in 
MCL cell lines. (Paper IV) 
 
3.2.6 Chromatin Immunoprecipitation (ChIP) 
 
Chromatin Immunoprecipitation (ChIP) is a widely used method to explore 
interactions of proteins and DNA in vivo. ChIP can be used to map DNA 
target sites for TFs and other chromosome-associated proteins. It used to 
identify TFs in a given promoter. A brief summary of the method, 
formaldehyde cross links proteins and DNA molecules, the DNA-protein 
complexes are then fragmented by sonication into uniform fragments of 200-
1000 base pair (bp), followed by immunoprecipitation with an antibody to the 
protein (for example TF) of interest, then the DNA fragments are purified and 
sequence are determined. 
 
Using ChIP assay, we demonstrated that SOX11 can directly target DBN1, 
SETMAR, and HIG2 in MCL. (Paper IV) 
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4 RESULTS AND DISCUSSION 
 
4.1 PAPER I 
 
Expression of cannabinoid receptors type of 1 and 2 in non Hodgkin 
lymphoma: Growth inhibition by receptor activation. 
 
The expression and function of the cannabinoid receptors in MCL has been 
described in the previous studies in our group [105, 106, 127]. The aim of this 
paper is to extend our knowledge about the cannabinoid receptors in 
lymphomas.   
 
In the present study, we investigated the expression of cannabinoid receptors 
in a series of B-cell lymphomas (n=62) including B-CLL/SLL, FL, DLBCL, 
MCL, BL, MZL, and pre-B-ALL. The mRNAs level of CB1 and CB2 was 
measured by quantitative real-time PCR. The majority of lymphomas 
expressed high levels of CB1 and/or CB2 mRNA compared to reactive 
lymphoid tissues. In MCL, uniform overexpression of the CB receptors was 
found, while the expression was highly variable in other lymphomas.   
 
Two splice variants of CB1 was recently identified in human brain [117], 
CB1a and CB1b. CB1a and CB1b showed different ligand binding affinity 
compared to the full length receptor. We investigated the expression of these 
two splice variants in the lymphoma tissues by PCR, and CB1a could be 
detected in 27 of the 62 samples (44%), while CB1b was not expressed. 
 
Next, we performed Western Blot and immunohistochemistry in patient 
samples from different entities expressing various CB1 mRNA levels. From 
the staining, we found that CB1 expression was not only detected in tumor 
cells but also in non malignant cells such as endothelium. In some lymphomas, 
CB1 expression was highly variable in the tumor population. The higher 
variable expression of CB receptors was also reported in other malignancies, 
such as glioma and breast cancer [126, 135]. 
 
Our previous results showed that treatment with cannabinoid receptor ligands 
can induce growth suppression and apoptosis in MCL [105, 106]. What could 
be the functional role of CB receptors in other lymphomas?  We investigated 
the levels of CB receptors on SKMM-2 derived from plasma cell leukemia, 
Raji and Namalwa (Burkitt lymphoma), MEC1 and MEC2 (chronic 
lymphocytic leukemia) and Rec1 (MCL), and the cells were treated with 
endocannabinoid analog R(+)-MA. To confirm the role of the receptors we 
applied nM doses of SR141716 (SR1) or SR144528 (SR2), specific antagonist 
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to CB1 and CB2 respectively. The studies showed R(+)-MA can induce 
caspase-3 activity and cell death in cell lines from MCL and CLL which 
express both CB1 and CB2 receptors, but not in BL cell lines expressing low 
levels of CB2 or in the plasma cell line expressing low levels of CB1. In MCL 
and CLL cell lines, the R(+)-MA induced cell death was abrogated by 
pretreatment with either SR1 or SR2, which suggested that ligation of both 
receptors is needed to induce cell death. 
 
To determine the therapeutic potential of cannabinoids in malignant 
lymphoma in vivo, we xenografted mice with human MCL cells JeKo 
expressing both CB1 and CB2 receptors. The mice were treated with R(+)-
MA twice per day by injection at the same site as the tumor cells injection. 
We found that the tumors in R(+)-MA treated mice grew slower and were 
significantly smaller compared with the control group. There was a 25% 
reduction in mitotic index in the tumors treated with R(+)-MA.  
 
These data suggest that targeting of the endocannabinoid system could be part 
of future therapies for certain of malignant lymphomas.. 
 
4.2 PAPER II 
 
High expression of 5-lipoxygenase in normal and malignant mantle 
zone B lymphocytes 
 
Our gene expression data showed that 5-LO expression is much higher in 
MCL than in reactive lymphoid tissues [127]. 
 
It was therefore of interest to investigate the expression and the activity of 5-
LO in MCL, as well as the expression of 5-LO in different subsets of normal 
B cells. In normal tonsillary B cells, higher expression of 5-LO was found in 
mantle zone B cells than GC B cells at both mRNA and protein level. 
 
A common viewpoint is that the different types of mature B cell lymphomas 
are “trapped” in a specific B cell stage. The cell of origin in most MCL is 
mantle zone B cells and FL originates from GC B cells. Then, we investigated 
if the 5-LO expression in MCL and FL resembled 5-LO expression observed 
in normal B subtype B cells. We found that most MCL samples showed high 
expression of 5-LO, while most of FL samples did not express 5-LO. Thus we 
can draw the conclusion that the 5-LO expression in MCL and FL 
corresponds to the subset of normal B cells from which they origin.  
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We further investigated the activity of 5-LO in MCL. MCL primary tumor 
cells and the MCL cell lines Granta 519, Rec-1 and JeKo-1 all expressed 5-
LO protein. When stimulated with Diamide plus AA and calcium ionophore, 
they produced similar amounts of LTB4 as human neutrophils.  
 
Put together, this study demonstrated that the expression of 5-LO in MCL can 
mimic their origin from mantle zone B cells. The activity of 5-LO in MCL is 
similar to previous findings in other reports using malignant B cells [159, 234]. 
However, it is still unclear how 5-LO can be activated in B cells in vivo.  
 
4.3 PAPER III 
 
The subcellular SOX11 distribution pattern identifies subsets of 
MCL: correlation to overall survival 
 
In this study, we investigated the expression of SOX11 in MCL cell lines and 
tumor tissues. 
 
First, we performed reverse transcriptase PCR (RT-PCR) to investigate the 
expression of SOX11 in lymphomas using RNA from human and mouse brain 
as positive controls. The primers had been published in a study of brain 
tumors [231].We found that SOX11 was strongly expressed in all the primary 
MCL samples (5/5), whereas only one of four reactive controls had weak 
expression. The expression of SOX11 mRNA was variable in 5/6 follicular 
lymphomas (FL). Among the cell lines, the MCL cell lines Granta 519 and 
Rec1 (cyclin D1+) were strongly positive as well as the breast cancer cell line 
MCF-7(cyclin D1+). T cell lines Jurkat and Molt-4 (cyclin D1-) weakly 
expressed SOX11 and plasma cell leukemia cell line SKMM-2 (cyclin D1+) 
had no expression. Thus, SOX11 mRNA was expressed in both lymphomas 
and reactive lymphoid tissues, and the expression seemed to be cyclin D1 
independent. 
 
Subsequently, we performed Western Blot to investigate the protein level of 
SOX11 in MCL cell lines, Granta 519, Rec-1 and JeKo. The results showed 
that there were obvious bands in Granta 519, Rec-1 and JeKo, but weak bands 
in Jurkat and Molt-4, no band in SKMM-2.  
 
Then, it is interesting to identify the distribution and localization of SOX11 in 
MCL tissues. We constructed a series of tissue microarrays (TMA). In the 
first TMA we compared 5 MCL, 7 FL, 5 SLL tumors and reactive lymphoid 
tissues. In MCL, SOX11 was expressed in the nucleus. We found that in 
reactive lymphoid tissues and FL, SOX11 was weakly expressed in some 
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biopsies and localized to the cytoplasm of the cells in germinal centre and in 
neoplastic follicles, respectively. The same pattern was found in few cells in 
SLL. These results were consistent with a recently published article analyzing 
more cases of SLL and FL [235]. However, when we analyzed the expression 
of SOX11 in the second TMA, constructed from a larger cohort of MCL, we 
found that while most MCL (48/53) had nuclear SOX11 staining, a few cases 
(5/53) had only cytoplasmic expression. Nuclear SOX11 expression therefore 
appears to detect most MCL tumors and can be considered as a new 
diagnostic marker in MCL. 
 
Tumor proliferation is the strongest prognostic marker in MCL. We therefore 
investigated if SOX11 expression was related to tumor cell proliferation. Our 
results showed that SOX11 negative MCL had moderate proliferation, but the 
overall survival of these patients was worse compared with those with nuclear 
expression. 
 
The present study demonstrates that SOX11 may act not only as a new 
diagnostic marker but also may carry information of clinical and biologic 
behavior of MCL. 
 
4.4 PAPER IV 
 
Gene expression profiling and chromatin immunoprecipitation 
identify DBN1, SETMAR and HIG2 as direct transcriptional 
targets of SOX11 in mantle cell lymphoma 
 
From our previous study on SOX11 and recent publications from other groups, 
we know that expression of SOX11 can be a diagnostic marker independent of 
cyclin D1 in MCL [235-239]. SOX11 can also detect the rare cyclin D1 
negative MCL. Certain other subtypes of B-cell lymphomas may be SOX11 
positive. However, the role of SOX11 in hematopoiesis is still unclear. In this 
study, we intended to determine the possible role of SOX11 in pathogenesis of 
MCL. 
 
In order to investigate the SOX11 target genes, we used siRNA to knock 
down SOX11 in the MCL cell line Granta 519, which expresses high SOX11 
protein but low SOX4 and SOX12 mRNA compared to other MCL cell lines. 
We evaluated the transfection efficiency of SOX11 siRNA by quantitative 
real time PCR and WB. The results showed that SOX11 was downregulated 
both at the transcriptional and translational level. We then tested the effect of 
SOX on the expression of the class-III ȕ-tubulin gene (TUBB3), which is up-
regulated by SOX11 in neural cells [190]. Our results showed that TUBB3 
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expression was reduced by SOX11 downregulation in MCL cell line Granta 
519.  
 
Subsequently, we used the Affymetrix platform to analyze the effect of 
SOX11 downregulation on global gene expression in Granta 519 cells. 26 
genes were significantly downregulated upon SOX11 siRNA treatment 
compared to cells treated with control siRNA. 
 
To further investigate the interaction between SOX11 and these 26 genes, we 
analyzed the correlation coefficients between SOX11 and these genes in two 
sets of gene expression data publically available from studies of primary MCL. 
We found a strong correlation between SOX11 expression level and the 
expression of DBN1, SETMAR and HIG2.  
 
To validate the results of the gene expression analysis, we performed 
quantitative RT-PCR in available primary MCL cells together with three 
MCL cell lines. We found a significant correlation between the expression of 
SOX11 and DBN1. 
 
We further investigated whether DBN1, SETMAR and HIG2 are the direct 
targets of SOX11 by ChIP assay, and it was shown that SOX11 was 
significantly recruited to DBN1, SETMAR, and HIG2 promoter regions close 
to transcription start site. DBN1 encodes for the actin binding protein Drebrin 
1 which plays a role in the morphogenesis in neurons. SETMAR encodes 
Metnase could influence cell division and response to cytostatic treatment 
[240].  
 
In summary, our study showed that SOX11 can directly target DBN1, 
SETMAR and HIG2. SOX11 may involve in cell migration and cell deviation. 
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5 CONCLUSIONS 
 
This thesis has focused on the expression and the functional role of four genes 
overexpressed in MCL, the cannabinoid receptor type 1 and 2, the key 
enzyme in leukotriene synthesis 5-lipoxygenase and the transcription factor 
SOX11. The major findings of this thesis are: 
 
Not only in MCL, but also in other mature B cell malignancies cases, the 
expressions of CB receptors were identified. Treatment of cannabinoid was 
found to induce apoptosis in vitro and to inhibit tumor growth in vivo. 
Therefore, targeting of the cannabinoid system may be of therapeutic use in 
lymphomas in the future. 
 
High 5-LO expression was found in MCL as well as in normal mantle zone B 
cells. 5-LO could be activated in MCL cell lines in vitro. However, the 
functional role of 5-LO in MCL is still unknown. 
 
SOX11 was expressed in most MCL and may serve as a new diagnostic 
marker. The SOX11 transcription factor can directly target DBN1, SETMAR 
and HIG2 and possibly regulates their expression in MCL.  
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6 FUTURE PERSPECTIVES 
 
We have identified that SOX11 can be a diagnostic marker in MCL, and it also can 
directly target DBN1, SETMAR and HIG2 through direct binding to DNA. Therefore, 
it is interesting to map SOX11 binding sites on a genome-wide scale. ChIP-on-ChIP is 
a good technique for this project.  
 
SOX11 protein can interact with other proteins to activate or repress the transcription of 
the targeted genes. However, to date, little is known about the role of SOX11 in 
hematopoiesis. Thus, a future perspective study would be interesting to investigate if 
SOX11 needs other partners to regulate genes and if so, what kinds of proteins are 
involved and in which ways to interact? Two-hybrid screening is considered to a good 
assay for discovering protein-protein interactions. 
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